European Medicines Agency Validates Gilead’s Marketing Application for Single Tablet Regimen Containing Rilpivirine, Emtricitabine and Tenofovir Alafenamide (R/F/TAF) for HIV Treatment
Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the company’s Marketing Authorization Application (MAA) for an investigational, once-daily single tablet regimen that combines emtricitabine 200 mg, tenofovir alafenamide 25 mg and rilpivirine 25 mg (R/F/TAF) has been fully validated and is now under evaluation by the European Medicines Agency (EMA). Emtricitabine and tenofovir alafenamide are marketed by Gilead Sciences and rilpivirine is marketed by Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
The data included in the application support the use of R/F/TAF for the treatment of HIV-1 infection in adults and pediatric patients 12 years and older.
“With this validation, R/F/TAF is now the third TAF-based filing under review by the EMA as we advance a portfolio of new treatment options that may offer high efficacy and favorable safety profiles,” said Norbert Bischofberger, PhD, Executive Vice President, Research and Development and Chief Scientific Officer, Gilead Sciences. “The R/F/TAF filing also represents the next step in our collaboration with Janssen to develop HIV treatments that potentially meet the diverse needs of people living with HIV.”
TAF is a novel investigational nucleotide reverse transcriptase inhibitor (NRTI) that has demonstrated high antiviral efficacy at a dose less than one-tenth that of Gilead’s Viread® (tenofovir disoproxil fumarate, TDF), as well as improved renal and bone laboratory parameters as compared to TDF in clinical trials in combination with other antiretroviral agents.
In addition to R/F/TAF, two other MAAs for TAF-based regimens are under review by the EMA. The MAA for an investigational, once-daily single tablet regimen containing elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir alafenamide 10 mg (E/C/F/TAF) was fully validated on December 23, 2014. The MAA for two doses of an investigational fixed-dose combination of emtricitabine and tenofovir alafenamide (200/10 mg and 200/25 mg) (F/TAF) was fully validated on May 28, 2015. Gilead has submitted New Drug Applications to the U.S. Food and Drug Administration for E/C/F/TAF, F/TAF and R/F/TAF on November 5, 2014, April 7, 2015, and July 1, 2015, respectively.
The current MAA is supported by a bioequivalence study demonstrating that administration of R/F/TAF results in the same blood levels of emtricitabine and TAF as those that are achieved with E/C/F/TAF (10 mg TAF dosage) and the same levels of rilpivirine as a 25 mg dose of rilpivirine (Edurant®) alone. The safety and efficacy of TAF is supported by a number of clinical studies in a range of patients with HIV, including treatment-naïve adults and adolescents, virologically suppressed adults who switched regimens and adults with mild-to-moderate renal impairment. In studies, TAF-based treatment (administered as E/C/F/TAF) resulted in non-inferior efficacy and improved renal and bone laboratory parameters as compared to TDF-based therapy (administered as E/C/F/TDF or Stribild®).
The R/F/TAF filing will be reviewed by the EMA under the centralized procedure, which, when finalized, may lead to the granting of marketing authorization by the European Commission, which is valid in all 28 member states of the European Union.
The R/F/TAF filing is the latest step in an expanded development and commercialization agreement between Gilead and Janssen, first established in 2009. Under this agreement, and pending the product’s approval, Gilead will be responsible for the manufacturing, registration, distribution and commercialization of the regimen in most countries, while Janssen will distribute it in approximately 17 markets and have co-detailing rights in several key markets. The original agreement was established for the development and commercialization of Eviplera®, marketed as Complera® in the United States.
A fourth investigational TAF-based regimen containing Gilead’s TAF, emtricitabine and cobicistat, and Janssen’s darunavir (D/C/F/TAF) is also under development under a separate licensing agreement. Under the agreement, Gilead is transferring to Janssen further development of the regimen and, subject to regulatory approval, the manufacturing, registration, distribution and commercialization of the product worldwide.
TAF and TAF-based regimens are investigational products and have not been determined to be safe or efficacious.
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California.
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the possibility that the EMA may not adopt a positive opinion in its evaluation and the European Commission may not grant marketing authorization for R/F/TAF. Further, the FDA, the European Commission and other regulatory authorities may not approve R/F/TAF, F/TAF, E/C/F/TAF and other TAF-based regimens in the currently anticipated timelines or at all, and marketing approvals, if granted, may have significant limitations on their use. As a result, R/F/TAF, F/TAF, E/C/F/TAF and other TAF-based regimens may never be successfully commercialized. In addition, Gilead may be unable to file for regulatory approval for D/C/F/TAF with regulatory authorities in the currently anticipated timelines. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2015, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.
The European SmPCs for Stribild, Eviplera, and Viread are available from the EMA website at www.ema.europa.eu .
Edurant is a registered trademark of Johnson & Johnson, or its related companies.
Stribild, Complera, Eviplera and Viread are registered trademarks of Gilead Sciences, Inc., or its related companies.
For more information on Gilead Sciences, please visit the company’s website at www.gilead.com , follow Gilead on Twitter ( @GileadSciences ) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
Gilead Sciences, Inc.
Patrick O’Brien, +1 650-522-1936
Ryan McKeel, +1 650-377-3548
Kristine Kelly, +44 (0)78 1086 8956
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
ThreatMetrix Exceeds 45% Annual Growth as Organizations Embrace Digital Identity as Must-Have Technology18.12.2017 13:00 | Pressemelding
ThreatMetrix ®, The Digital Identity Company®, today announced 45 percent growth in billings year-on-year, as implementing digital identity solutions became a key priority for organizations in 2017. In the past quarter, average daily transaction volume processed by ThreatMetrix surged from 75 million to more than 100 million transactions, contributing rich data to the world’s only digital identity graph. Throughout 2017, nearly 150 new companies per quarter were added to the Digital Identity Network®, giving ThreatMetrix customers an unparalleled global view into true digital identity and user trust. “Organizations of all shapes and sizes are embracing ThreatMetrix ID™ to recognize true customers, operate digital businesses securely and profitably, and improve the user experience – all without compromising privacy,” says Frank Teruel, chief finance off
DWC Secures € 10,8 M From GEM Global18.12.2017 10:54 | Pressemelding
Diversified World Corporation 3.0 spa, (“DWC 3.0” or “the Company“) is a listed company at Euronext Access Market in Paris, Symbol (MLDWC:FP). Today, DWC 3.0 is pleased to announce that it has signed a contract for a € 10, 8 million funding facility under a three years warrants agreement, (the “Agreement”) with GEM Global Yield Fund, the private alternative investment group. These € 10,8 million will be raised by issuing 30 million warrants that can be exercised within three years by GEM Global Yield Fund, at the price which represents the nominal value of the share. The Company will sign within a very short time an agreement with a specialist sponsor in order to upgrade its listing to GROWTH Euronext Market in Paris. About DWC 3.0 The Company considers important its presence within the Fine Art sector since Merrill Lynch -Cap Gem
EURid Hosts Green Discussion Panel at The 2017 Internet Governance Forum in Geneva18.12.2017 10:00 | Pressemelding
EURid understands the importance that possessing a neutral carbon footprint has on the planet, which is why it has, and continues to support sustainable projects all over the world. Since May 2012, EURid has been Eco-Management and Audit Scheme (EMAS) certified, which reflects its continuous pursuit towards being a sustainable organisation. As part of its EMAS certification, EURid has issued and instituted an environmental policy, through which it has achieved the following goals: In 2015, EURid joined forces with the environmental Spanish non-profit organisation FAPAS. A number of fruit trees were planted in Asturias, Spain, an area populated by the endangered European brown bear. EURid also purchased verified CO2 credits to contribute to the Ecomapuà project with the goal of conserving the rich biodiversity in the Amazon.
BearingPoint Achieves Platinum Status in the Salesforce Consulting Partner Program18.12.2017 09:00 | Pressemelding
Management and technology consultancy BearingPoint is officially designated a Salesforce Platinum Consulting Partner. The prestigious Platinum Consulting Partner status marks an important milestone for the consultancy and demonstrates its commitment to help the world's most innovative brands enhance their customer experience and run their business in the cloud by leveraging the power of the Salesforce platform. With many new engagements this year, BearingPoint has also been able to significantly increase the number of Salesforce certifications while delivering great value to clients by integrating the Salesforce platform into their business. “Reaching the Platinum Consulting Partner status within less than 3 years basically coming from zero has been a huge feat and shows the focus, dedication, and energy of our fast-growing Salesforce community at BearingPoint,” says Markus
Timor Telecom Enhances International Voice Connections in Timor-Leste Through SES Networks18.12.2017 07:55 | Pressemelding
Timor Telecom (TT), the largest telecommunications operator in Timor-Leste, has expanded its partnership with SES Networks to enable international voice traffic between Timor-Leste and the rest of the world, SES announced today. Under the new agreement, TT will contract capacity on the high-powered NSS-12 geostationary earth orbit (GEO) satellite to establish a point-to-point link connecting Dili, Timor with Sintra, Portugal. Today, residents of Timor-Leste benefit from high speed 4G/LTE mobile data and broadband services provided by TT, which are powered by SES’s O3b medium earth orbit (MEO) satellite network. With its capacity uptake on NSS-12, TT will broaden its suite of services with the carriage of international voice traffic between Timor-Leste and the rest of the world. This enables TT to continue empowering local communities with superior services and to meet all th
Steeper Energy Announces EUR 50.6 M (DKK 377 M) Advanced Biofuel Project with Norwegian-Swedish joint venture Silva Green Fuel in Licensing Deal18.12.2017 07:00 | Pressemelding
Steeper Energy, a Danish-Canadian clean-fuel company, is partnering with Silva Green Fuel, a Norwegian-Swedish joint venture, to construct a EUR 50.6 M (DKK 377M) industrial scale demonstration plant at a former pulp mill located in Tofte, Norway leading to a future commercial scale project. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171217005029/en/ Steeper will license its proprietary Hydrofaction™ technology to Silva, who will build the facility over the next 18 months. The demonstration plant will use woody residues as feedstock that are converted to renewable crude oil and, in turn, will be upgraded to renewable diesel, jet or marine fuel. Steeper’s Hydrofaction™ technology was selected by Silva after an exhaustive due diligence review of some 40 other technologies. Hydrofaction™ harnesses water
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom